Consummating a deal under lockdown: Roche and Arrakis in a BioCentury podcast

For its first partnership, RNA-targeting therapeutics developer Arrakis chose Roche for a multitarget deal that landed the biotech a $190 million upfront payment, while allowing it to remain an independent company. Arrakis stands to gain into the billions if it satisfies regulatory and other conditions, in what is one of Roche’s biggest deals with a company at this stage.

From a dinner in Basel to a meeting consummated on Zoom, the architects of the deal, Roche’s James Sabry and Arrakis CEO Michael Gilman, discuss with BioCentury Editor in Chief Simone Fishburn how the partnership came together, on a BioCentury This Week -- Special Report PODCAST. ...